新上海三阴性乳腺癌治疗显示56.8%的试验成功率。 New Shanghai treatment for triple-negative breast cancer shows 56.8% success rate in trials.

上海研究人员开发了一种新的治疗三联阴性乳腺癌的疗法,将传统化疗与Camrelizumab(一种免疫疗法药物)相结合。 Shanghai researchers have developed a new treatment for triple-negative breast cancer, combining traditional chemotherapy with Camrelizumab, an immunotherapy drug. 第三阶段临床试验涉及中国40家医院的441名病人,结果显示,病理学完全反应率为56.8%,而安慰剂组为44.7%。 The phase III clinical trial, involving 441 patients across 40 hospitals in China, showed a 56.8% pathological complete response rate, compared to 44.7% in the placebo group. 这项研究在《美国医学协会期刊》上发表,为在这种具有攻击性的癌症类型中取得更好的结果带来了希望。 This study, published in the Journal of the American Medical Association, offers hope for better outcomes in this aggressive cancer type.